1. Varga, J, Trojanowska, M, Kuwana, M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2017; 2(3): 137–152.
Google Scholar | SAGE Journals2. Shreiner, AB, Murray, C, Denton, C, et al. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 2016; 1(3): 247–256.
Google Scholar | SAGE Journals3. Hoffmann-Vold, AM, Volkmann, ER. Gastrointestinal involvement in systemic sclerosis: effects on morbidity and mortality and new therapeutic approaches. J Scleroderma Relat Disord 2021; 6(1): 37–43.
Google Scholar | SAGE Journals4. Kowal-Bielecka, O, Fransen, J, Avouac, J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76(8): 1327–1339.
Google Scholar | Crossref | Medline5. Nagaraja, V, McMahan, ZH, Getzug, T, et al. Management of gastrointestinal involvement in scleroderma. Curr Treatm Opt Rheumatol 2015; 1(1): 82–105.
Google Scholar | Crossref | Medline6. Stern, EK, Carlson, DA, Falmagne, S, et al. Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterol Motil 2018; 30(2): 13247.
Google Scholar | Crossref7. Sugano, K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol 2018; 11: 1756283X17745776.
Google Scholar | SAGE Journals8. Hoshino, S, Kawami, N, Takenouchi, N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 2017; 95(2): 156–161.
Google Scholar | Crossref | Medline9. Yamashita, H, Kanamori, A, Kano, C, et al. The effects of switching to vonoprazan, a novel potassium-competitive acid blocker, on gastric acidity and reflux patterns in patients with erosive esophagitis refractory to proton pump inhibitors. Digestion 2017; 96(1): 52–59.
Google Scholar | Crossref | Medline10. Akiyama, J, Hosaka, H, Kuribayashi, S, et al. Efficacy of vonoprazan, a novel potassium-competitive acid locker, in patients with proton pump inhibitor-refractory acid reflux. Digestion 2020; 101(2): 174–183.
Google Scholar | Crossref | Medline11. van den Hoogen, F, Khanna, D, Fransen, J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2013; 65(11): 2737–2747.
Google Scholar | Crossref | Medline12. Shirai, Y, Okazaki, Y, Inoue, Y, et al. Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol 2015; 67(2): 498–507.
Google Scholar | Crossref | Medline13. Lundell, LR, Dent, J, Bennett, JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45(2): 172–180.
Google Scholar | Crossref | Medline14. Kusano, M, Shimoyama, Y, Sugimoto, S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 2004; 39(9): 888–891.
Google Scholar | Crossref | Medline15. Kuribayashi, S, Iwakiri, K, Shinozaki, T, et al. Clinical impact of different cut-off values in high-resolution manometry systems on diagnosing esophageal motility disorders. J Gastroenterol 2019; 54(12): 1078–1082.
Google Scholar | Crossref | Medline16. Kahrilas, PJ, Bredenoord, AJ, Fox, M, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27(2): 160–174.
Google Scholar | Crossref | Medline17. Sakurai, Y, Mori, Y, Okamoto, H. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects: a randomised open-label cross-over study. Aliment Pharmacol Ther 2015; 42(6): 719–730.
Google Scholar | Crossref | Medline